RLAY’s zovegalisib reports efficacy and safety progress in trials
RLAY says zovegalisib has shown strong efficacy and safety data across its breast cancer and vascular anomalies programs, with regulatory updates and new trial launches expected soon as commercial preparations move ahead.
Significant progress was reported in both breast cancer and vascular anomalies programs, with zovegalisib showing strong efficacy and safety data. Regulatory updates and new trial launches are expected soon, and commercial preparations are underway for chronic therapies in large patient populations…